Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Vir Biotechnology is a clinical-stage immunology company developing T-cell and antibody-based therapies for infectious diseases and cancer. The company's lead program focuses on chronic hepatitis B virus (HBV) infection, with VIR-2218 and VIR-3434 in Phase 2 trials targeting functional cure. Vir previously commercialized sotrovimab for COVID-19 with GSK, generating significant revenue before demand collapsed, and now operates as a cash-burning R&D entity dependent on clinical trial success and partnership economics.
Vir operates a partnership-driven model where it co-develops therapies with pharmaceutical partners (primarily GSK) who provide upfront payments, milestone payments, and share development costs in exchange for profit-sharing or royalties. The company's negative gross margin reflects R&D expenses allocated against minimal current revenue. Value creation depends entirely on clinical trial success leading to regulatory approval and commercialization, at which point the company would receive royalties or profit-share from partners. The HBV franchise represents the primary near-term value driver, with potential for $500M+ annual peak sales if functional cure is achieved. Operating leverage is currently negative but would flip dramatically positive upon commercialization as fixed R&D costs are absorbed by product revenue.
Clinical trial data readouts for VIR-2218 and VIR-3434 HBV programs, particularly HBsAg reduction and functional cure rates
Partnership announcements or amendments with GSK or new pharma partners, including upfront payments and milestone structures
FDA or EMA regulatory decisions on IND applications, trial design approvals, or breakthrough therapy designations
Cash runway updates and financing activities (equity raises, debt facilities) given $400M+ annual cash burn
Competitive developments in HBV space from Gilead, GSK, Roche, or emerging biotech competitors
Clinical trial failure risk is existential - HBV programs could fail to demonstrate functional cure or acceptable safety, eliminating primary value driver and requiring pivot or wind-down
Regulatory pathway uncertainty for functional cure endpoints in HBV, as FDA has not established clear approval standards beyond viral suppression
Infectious disease market volatility demonstrated by sotrovimab collapse, where pandemic-driven demand evaporated and left company with stranded manufacturing capacity
Intense competition in HBV functional cure space from well-capitalized competitors including Gilead (bepirovirsen), GSK (bepirovirsen partnership), Roche, and Assembly Biosciences with potentially faster timelines
GSK partnership concentration risk - over-reliance on single partner for funding, development support, and commercialization creates vulnerability if GSK reprioritizes or terminates collaboration
Technology risk that T-cell and antibody approaches may be superseded by gene editing (CRISPR) or other novel modalities in infectious disease treatment
Cash burn of $400M+ annually with minimal revenue creates 12-18 month runway requiring dilutive equity raises or partnership deals to avoid liquidity crisis
Negative working capital dynamics as R&D expenses accelerate with Phase 2/3 trial expansion while revenue remains negligible
Equity dilution risk from future financings given $1.0B market cap and need for potentially $500M+ additional capital before potential commercialization
low - As a pre-revenue clinical-stage biotech, Vir's business model is insulated from GDP fluctuations and consumer spending patterns. Clinical trial timelines, regulatory processes, and scientific outcomes drive value rather than economic cycles. However, severe recessions can impact partnership economics if pharma partners reduce R&D budgets or delay milestone payments.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (HBV commercialization unlikely before 2028-2029). Higher rates also reduce present value of potential milestone payments and increase opportunity cost for investors holding cash-burning biotechs. Conversely, Vir benefits modestly from higher yields on its $500M+ cash balance. Financing costs are minimal given low debt levels (0.13x D/E), but equity raises become more dilutive in high-rate environments as growth stock valuations compress.
Minimal - Vir maintains strong liquidity with 7.25x current ratio and minimal debt. The company is not dependent on credit markets for operations, though access to equity capital markets is critical for funding ongoing cash burn. Tightening credit conditions indirectly impact the company by reducing risk appetite for speculative biotech investments and compressing valuation multiples.
growth - Attracts speculative biotech investors and hedge funds taking binary bets on clinical trial outcomes. The stock appeals to investors with high risk tolerance seeking asymmetric upside from potential HBV franchise worth $2B+ if successful, versus current $1B market cap. Recent 66% six-month rally suggests momentum traders are also active. Not suitable for value or income investors given negative profitability, no dividends, and cash-burning profile.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial data, FDA decisions). The stock's -22.5% one-year return despite recent 66% six-month surge demonstrates whipsaw price action. Beta likely exceeds 1.5x given small-cap biotech sector characteristics and single-asset concentration risk in HBV franchise.
